Neutralization (in a conventional sense) of influenza virus is a function of antibody to the hemagglutinin antigen. It has been suggested that anti-neuraminidase antibody can produce apparent neutralization by interfering with viral release and by steric inhibition of virus adsorption (5, 6) . Consequently, the use of conventional tissue culture neutralization tests for determinations of hemagglutinin antibody must take into account the presence of antibody to the enzyme antigen in a test specimen. The following study assesses the effect of anti-neuraminidase antibody in serum neutralization tests using wild and recombinant (hemagglutininspecific) virus.
Serum specimens from adult male volunteers who participated in evaluation of an influenza virus vaccine monospecific for neuraminidase were used in this study (Couch et al., unpublished data). The experimental vaccine employed, X-32 (4), consisted of an inactivated, antigenically hybrid virus possessing the hemagglutinin of A/equine/Prague/1/56 virus and the neuraminidase of an H3N2 recombinant, X-31 (2 
H3N1(PRS, and by the neuraminidase inhibition
test using approximately three enzyme units of HON2(HK,, as previously described (1, 6). In the neutralization procedure, virus-serum mixtures remained in the tissue culture system during the test period.
The data in Table 1 show that determinations for hemagglutinin antibody by neutralization tests may be influenced by the presence in the assay system of antibody to the neuraminidase antigen. This is clearly shown by postvaccination and post-virus-challenge serological results among individuals in the X-32 vaccine group. The relative frequencies and levels of antibody response were significantly greater in tests using H3N2 than in those employing H3N1, the antigenic hybrid containing an antigenically unrelated neuraminidase (in each case, P < 0.005). In addition, a similar contribution of anti-neuraminidase antibody to the level of response is suggested by the higher mean titer in sera after virus challenge in the type B vaccine group. Although not shown, postvaccination and post-virus-challenge serum specimens from three volunteers in the X-32 group were tested against H3N2 virus by neutralization tests in which serum-virus mixtures were removed' from cell cultures after a 60-min incubation period. The results were similar to those seen in tests using H3N1 virus. None of the individuals exhibited antibody activity (< 1: 2) in their postvaccination serum specimens, and the mean antibody titer was twofold less after virus challenge. By contrast, in tests where H3N2 virus remained in the cell culture system during the test period, the mean postvaccination and post-virus-challenge antibody titers 
